Financials Talphera, Inc.

Equities

TLPH

US00444T2096

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
1.05 USD -6.25% Intraday chart for Talphera, Inc. +6.06% +42.86%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 167.9 122.5 76.65 18.53 12.46 17.82 - -
Enterprise Value (EV) 1 178.4 101.5 76.65 18.53 12.46 17.82 17.82 17.82
P/E ratio -3.15 x -2.64 x -1.93 x 0.4 x -0.57 x -1.11 x -1.12 x -1.35 x
Yield - - - - - - - -
Capitalization / Revenue 73.4 x 22.6 x 27.2 x 10.5 x 19.1 x 26.1 x 7.12 x 1.44 x
EV / Revenue 73.4 x 22.6 x 27.2 x 10.5 x 19.1 x 26.1 x 7.12 x 1.44 x
EV / EBITDA -3,195,825 x -3,132,844 x - - - - - -
EV / FCF -3,072,261 x -3,035,816 x - - - - - -
FCF Yield -0% -0% - - - - - -
Price to Book -4.05 x -1.9 x - - - - - -
Nbr of stocks (in thousands) 3,979 4,941 6,841 8,198 16,952 16,969 - -
Reference price 2 42.20 24.80 11.20 2.260 0.7350 1.050 1.050 1.050
Announcement Date 20-03-16 21-03-15 22-03-10 23-03-30 24-03-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2.289 5.416 2.818 1.771 0.651 0.6825 2.504 12.33
EBITDA -52.54 -39.11 - - - - - -
EBIT 1 -54.2 -40.96 -35.96 -36.63 -16.89 -20.77 -20.39 -17.55
Operating Margin -2,368.06% -756.33% -1,276.26% -2,068.49% -2,594.32% -3,042.86% -814.44% -142.33%
Earnings before Tax (EBT) 1 -53.24 -40.38 -35.09 47.77 -10.29 -25.1 -24.69 -18.29
Net income 1 -53.24 -40.38 -35.1 42.33 -18.4 -20.16 -21.14 -18.75
Net margin -2,325.91% -745.55% -1,245.53% 2,390.12% -2,825.96% -2,954.58% -844.26% -152.07%
EPS 2 -13.40 -9.400 -5.800 5.720 -1.290 -0.9500 -0.9400 -0.7750
Free Cash Flow -54.65 -40.36 - - - - - -
FCF margin -2,387.51% -745.2% - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-03-16 21-03-15 22-03-10 23-03-30 24-03-06 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 1.862 0.002 0.442 0.57 0.507 0.252 - 0.253 0.117 0.281 - - - -
EBITDA - - - - - - - - - - - - - -
EBIT 1 -8.633 -8.175 -8.995 -13.57 -6.632 -7.433 -5.328 -3.969 -3.309 -4.283 -5.2 -6.5 -7 -6.4
Operating Margin -463.64% -408,750% -2,035.07% -2,381.23% -1,308.09% -2,949.6% - -1,568.77% -2,828.21% -1,524.2% - - - -
Earnings before Tax (EBT) 1 -8.375 -7.917 -8.674 70.67 -6.739 -7.485 -8.152 -4.425 -1.416 -4.51 -5.2 -6.5 -7 -6.4
Net income 1 -8.375 -7.917 -8.674 70.66 -6.936 -7.484 -8.152 -4.371 -1.357 -4.517 -5.2 -6.5 -7 -6.4
Net margin -449.79% -395,850% -1,962.44% 12,397.02% -1,368.05% -2,969.84% - -1,727.67% -1,159.83% -1,607.47% - - - -
EPS 2 -1.400 -1.200 -1.200 9.600 -0.9400 -1.000 -0.7500 -0.4000 -0.0800 -0.2500 -0.2150 -0.2550 -0.2200 -0.2050
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 21-11-15 22-03-10 22-05-16 22-08-11 22-11-14 23-03-30 23-05-10 23-08-10 23-11-08 24-03-06 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 10.5 - - - - - - -
Net Cash position - 21 - - - - - -
Leverage (Debt/EBITDA) -0.1992 x - - - - - - -
Free Cash Flow -54.7 -40.4 - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share -10.40 -13.10 - - - - - -
Cash Flow per Share - -9.030 - - - - - -
Capex 3.47 1.86 1.83 0.36 0.1 - - -
Capex / Sales 151.59% 34.25% 64.83% 20.55% 15.36% - - -
Announcement Date 20-03-16 21-03-15 22-03-10 23-03-30 24-03-06 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.05 USD
Average target price
5.125 USD
Spread / Average Target
+388.10%
Consensus
  1. Stock Market
  2. Equities
  3. TLPH Stock
  4. Financials Talphera, Inc.